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Framingham 10-year high risk cohort was more likely to be deﬁned among less edu-
cated, unmarried, overweight/obese people reporting higher numbers of comorbidities, 
poorer general health, and higher use of public insurance.
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OBJECTIVES: The objective of this study was to evaluate the effects of nicotine gum 
price on gum acquisition and smoking abstinence in an over-the-counter (OTC) 
setting. METHODS: Adult smokers (N = 270) were randomized to acquire nicotine 
gum from a study clinic for $20/box, $10/box, or without charge. They were then 
followed at 2, 6, 12, and 26 weeks after their initial gum purchase. At each time point, 
seven-day point-prevalent abstinence was assessed. Negative binomial regression was 
used to model the number of acquired boxes of nicotine gum as a function of interven-
tion group, time of follow-up, and the interaction of these two factors. Smoking 
abstinence was modeled separately at each time point using exact multiple logistic 
regression. All effectiveness analyses were performed by intent to treat. RESULTS: 
The mean (SD) number of boxes of gum acquired prior to the 2-week visit was 1.04 
(1.21), 1.53 (1.48), and 4.01 (2.26) in the $20/box, $10/box, and $0/box arms, 
respectively. The mean (SD) number of boxes acquired over the course of the study 
was 2.11 (3.89), 3.48 (6.69), and 11.42 (12.72) in the $20/box, $10/box, and $0/box 
arms, respectively. Differences in the number of boxes of gum acquired across inter-
vention groups and time points were statistically signiﬁcant (p < 0.001). At 26 weeks, 
abstinence rates were 1.08%, 6.74%, and 10.47% in the $20/box, $10/box, and $0/
box arms, respectively. Relative to the $0/box arm, the OR [95% CI] for abstinence 
in the $20/box and $10/box arms was 0.094 [0.004, 0.590] and 0.620 [0.197, 1.845], 
respectively. CONCLUSIONS: This is the ﬁrst study to demonstrate in an OTC setting 
that the price of nicotine replacement therapy has an effect not only on medication 
acquisition but also on medication effectiveness. Price was also observed to have a 
deleterious effect on subject retention.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is characterized by 
chronic inﬂammation throughout the airways, parenchyma and pulmonary vascula-
ture. Three classes of inhaled drugs are prescribed for the treatment of moderate-to-
severe COPD: anticholinergic bronchodilators, beta agonist bronchodilators and 
inhaled corticosteroids. All three have different mechanisms of action, therefore ena-
bling them to be used in combination. Canadian guidelines now recommend use of 
triple therapy (both bronchodilators plus steroid) for the management of moderate-
to-severe COPD and the anticipated increase in the use of triple therapy may have an 
impact on publicly-funded drug programs. The objective of this research was to 
determine the clinical effectiveness of triple therapy for the management of moderate-
to-severe COPD. METHODS: A systematic literature search was conducted to identify 
randomized controlled trials of ≥ 3 months duration, evaluating triple therapy in 
COPD management. Similar clinical outcomes were pooled for meta-analyses. 
RESULTS: Of the 2305 citations identiﬁed four were retained for evaluation. Triple 
therapy was tiotropium plus a ﬂuticasone/salmeterol combination inhaler in 3 trials, 
with the fourth evaluating tiotropium plus budesonide/formoterol. The monotherapy 
comparator for all trials was tiotropium. Meta-analyses were conducted for quality 
of life, lung function and exacerbations. There was a signiﬁcant improvement in St 
George’s Respiratory Questionnaire scores: WMD 3.75 (95%CI: 1.56,5.64) and lung 
function: WMD 0.06 L (95% CI: 0.03, 0.09). For acute/severe exacerbation rate the 
pooled OR 0.57 (95% CI: 0.23,1.38) was not signiﬁcant. Signiﬁcant reduction in 
COPD hospitalization rate was also reported using different data types (RR 0.53 and 
RR 0.35). CONCLUSIONS: There is signiﬁcant heterogeneity across the trials provid-
ing the exacerbation data therefore interpretation of the results of the meta-analyses 
is difﬁcult. Pooled results are not signiﬁcant but individual trial results are conﬂicting. 
Triple therapy does improve quality of life, lung function and COPD hospitalization 
rates compared to monotherapy but incremental beneﬁt of triple therapy compared 
to dual therapy is still unanswered.
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OBJECTIVES: We examined effectiveness of spirometry for children with asthma in 
the employer-based insured population using propensity score method. METHODS: 
A retrospective study of 25,664 children with asthma aged 5 to 18 was conducted 
with 2005–2007 MarketScan data. The cohort was limited to continuously enrolled 
children who had at least one emergency department visit or hospitalization (an acute 
asthma event) due to asthma in 2005–2006. A child was classiﬁed as having a spi-
rometry test if that child had at least one spirometry test in 2005- 2006. The main 
health outcome measure was the number of acute asthma events in 2007. We used 
propensity score matching (PSM) method to control for confounding between the 
groups with and without spirometry test. Four different PSM strategies were used to 
ﬁnd for each child with spirometry all observations among children with no spirometry 
with close propensity scores: one neighbor (0.02), ﬁve neighbors (0.02), local linear 
regression and kernel matching with bandwidth 0.8. The treatment group was deﬁned 
as all children who had a spirometry test while four separate control groups were 
generated based on each of four PSM strategies previously deﬁned. RESULTS: Chil-
dren with a spirometry test had similar demographic, geographic, health status and 
health plan type characteristics to those without; however children with a spirometry 
test had on average more controller and reliever medication reﬁlls and specialist visits 
related to asthma compared to children without a spirometry The average number 
of acute asthma events in 2007 in the treatment group was 0.105, while that 
number was 0.117, 0.119, 0.115 and 0.112 in the control groups, as previously 
deﬁned. Thus having a spirometry test was associated with 6% to 11% fewer acute 
asthma events (p < 0.01) depending on the PSM strategies used. CONCLUSIONS: 
Spirometry testing had a signiﬁcant positive association with reduced frequency of 
serious asthma events.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is a respiratory dis-
order characterized by progressive, partially reversible, airway obstruction. Chronic 
bronchitis (CB) is a subset of COPD. We compared CB epidemiology and related 
resource utilization in Ontario, between 2003 and 2009. METHODS: A 10-year 
database containing 176,000 patient records, from 53 general practitioners, was used 
to extract COPD records. Index dates were July 2003 and July 2009 for patients aged 
40+. Prevalence was based on a diagnosis of COPD and CB deﬁned by 1)ICD9/ICD10 
codes; 2)Symptoms (chart text entries); or 3)Unique COPD drug therapy (i.e. anticho-
linergics). Disease severity stratiﬁcation for CB patients was based on 2008 Canadian 
Thoracic Society guidelines for patients with spirometry (12 months prior to index 
date) documenting FEV1 and FEV1/FVC of <0.7. Related resource utilization (12 
months prior to index date): specialists visits, ER visits, hospitalizations, were cap-
tured. Comparisons between 2003 and 2009 are reported. RESULTS: In 2003, 76,143 
records were examined and 6742 COPD patients were identiﬁed (8.9% prevalence, 
63% diagnosed with CB, mean age 71 ± 8) compared to 8.5% prevalence in 2009 
(8495 patients/99,941 records; 66% with CB, mean age 69 ± 9). 74% and 66% of 
CB patients have spirometry for stratiﬁcation in 2003 and 2009 respectively. Severity 
stratiﬁcation (CB patients) into mild, moderate, severe and very severe for 2003 was: 
54%, 15%, 10%, 21% and in 2009: 52%, 22%, 7%, 18%. There were 674 CB 
related hospitalizations in 2003 and 589 in 2009, using the spirometry subgroup. 
From these hospitalizations: 32% vs 25% (2003 vs 2009); 43% vs. 46% and 9% vs. 
25% were found in moderate, severe and very severe groups respectively. Differences 
between ER and specialist visits were also noted. CONCLUSIONS: CB constitutes the 
majority of COPD prevalence. Resource utilization from 2003 and 2009 remained 
high despite perceived improvements in COPD/CB management.
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OBJECTIVES: This study determined the incidence rate, cumulative incidence rate 
(CIR) and cluster of diagnosis in the patients under PMV (prolonged mechanical 
ventilation). METHODS: The reimbursement data of National Health Insurance of 
Taiwan was transformed into a research database by the National Health Research 
Institutes, in which there were 8,906,406 people who ever used mechanical ventilation 
at least once during the period of 1997–2007. A random sample of the above popula-
tion with 3.4:1 ratio provided a database of 2,619,534 subjects under mechanical 
ventilation for more than 21 days. The incidence rates, cumulative incidence rates 
were calculated and their characteristics were explored by data mining and cluster 
analysis. RESULTS: A total of 50,481 new PMV patients were found during the study 
period with a mean age of 72 years. The age speciﬁc incidence rates showed an 
increased trend as the age grew old. The highest annual incidence rate of PMV in 
people who were older than 85 years increased from 1,182 to 2,584 per 100,000 
between 1998 and 2004, and then decreased 2,046 per 100,000 in 2007. The CIR 
(17–85 years) increased from 0.103 to 0.183 between 1998 and 2004, and then 
decreased 0.145 in 2007. The results of data mining showed that about three-fourths 
of PMV patients developed from generalized infection (septicemia), infections of 
respiratory system or urinary tract, or cardiovascular diseases affecting lung. The 
latent class model yielded 3 clusters in patients older than 85 years: septicemia, symp-
toms involving cardiovascular system and chronic bronchitis. CONCLUSIONS: In 
addition to chronic bronchitis, septicemia, and cardiovascular diseases complicated 
with respiratory failure appeared to be the major causes for PMV with a CIR17–85 of 
1/7 to 1/10 in Taiwan and deserve future studies of prevention and treatment.
